A White House deal puts weight-loss drugs on a path into Medicare at $245 a month
Lilly and Novo Nordisk agreed to sell their obesity drugs to public plans at a fixed price, with a small copay for Medicare patients and lower cash prices for everyone else.
Who feels it
-
Patients
Rethink
If you are on Medicare and meet the criteria, a copay of about $50 a month is the stated goal once coverage starts.
-
Payers
Rethink
Public plans gain a known price but also a large new group of eligible members.
-
Prescribers
Adjust
Expect new eligibility rules and paperwork; the criteria are tied to weight plus related conditions.
-
Pharmacies
Adjust
A fixed public price changes reimbursement math; watch how dispensing fees are set.
-
Sellers
Adjust
Both makers trade price for volume and a public channel, and face a tariff truce in return.
What was agreed
The two largest makers of GLP-1 medicines agreed with the US government on a single price for public plans: about $245 a month for semaglutide and tirzepatide products bought by Medicare and Medicaid. Medicare patients who qualify were told to expect a copay of around $50.
The deal also set lower self-pay prices through a government-linked purchasing site, starting around $350 a month for injections and lower for future pills.
Who qualifies
Coverage is meant for people with obesity plus related conditions, not for weight loss alone. The exact criteria were left to the agencies that run the programs.
Why it matters at the counter
Until now, Medicare law blocked coverage of drugs used for weight loss. This deal does not change that law; it relies on a separate program route. That is why the timing is a plan, not a promise.
| Before | After (planned) | |
|---|---|---|
| Medicare, obesity only | Not covered | Covered with criteria |
| Price to public plans | List minus rebates | About $245 |
| Patient copay | Full price | About $50 |
What to watch
- The written rules for eligibility and the actual start date.
- Which state Medicaid programs opt in.
- Whether private insurers use the public price as a lever in their own talks.
Source White House fact sheet and Eli Lilly and Novo Nordisk statements, 6 November 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
